Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: The phase 3 KEYNOTE-716 study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Georgina V. Long, Jason J. Luke, Muhammad Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion-Sileni, John M. Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S. Carlino, Larry Wu, Mizuho Fukunaga-Kalabis, Clemens Krepler, Alexander M. Eggermont, Paolo Antonio Ascierto
Institutions: The University of Sydney, Melanoma Institute Australia, UPMC Hillman Cancer Center, Edith Cowan University, Fiona Stanley Hospital, Hospital Universitario Virgen Macarena, Fondazione IRCCS Istituto Nazionale dei Tumori, The Maria Sklodowska-Curie National Research Institute of Oncology, Ospedale Policlinico San Martino, Poznan University of Medical Sciences, Greater Poland Cancer Center, Istituto Oncologico Veneto, Université Paris-Saclay, Institut Gustave Roussy, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Istituto Dermopatico dell'Immacolata, Istituti di Ricovero e Cura a Carattere Scientifico, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, Merck & Co., Inc., Rahway, NJ, USA (United States), University Medical Center Utrecht, Princess Máxima Center, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4293083652